NASDAQ · ORKA
Oruka Therapeutics, Inc.
$95.41-$1.24 (-1.28%)
Oruka Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 17.42% below the high.
Loading market information…
NASDAQ · QLI · USD
Stock price, dividends, earnings
Quote as of Aug 9, 2024, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Qilian International Holding Group Limited’s quoted price sits in the upper half of its reported 52-week range, 19.13% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Qilian International Holding Group Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Qilian International Holding Group Limited (QLI), founded in 2019 and headquartered in Jiuquan, People's Republic of China, focuses on the research, development, and production of active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMDs), and a variety of other products. The company's diverse offerings include licorice-derived products such as Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, supplied to pharmaceutical companies for manufacturing traditional licorice tablets; and Qilian Shan licorice liquid extract, a key ingredient for producing compound licorice oral solutions. QLI also produces Qilian Shan oxytetracycline tablets, used to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and humans, alongside Qilian Shan oxytetracycline APIs for other pharmaceutical manufacturers. Its TCMD line features Ahan antibacterial paste, designed for addressing stubborn chronic skin ailments. Furthermore, the company provides heparin sodium preparations to pharmaceutical firms for developing medications related to cardiovascular diseases, cerebrovascular conditions, and hemodialysis. Beyond the medical sector, Qilian International offers Zhu Xiaochang natural sausage casings for culinary applications. In agriculture, it produces Xiongguan organic fertilizers, formulated to improve crop yield, enhance soil chemical properties, and reduce compaction, as well as Xiongguan organic-inorganic compound fertilizers to stimulate plant growth.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:08 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$95.41-$1.24 (-1.28%)
Oruka Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 17.42% below the high.
CHF 1.02-CHF 0.05 (-4.67%)
SHL Telemedicine Ltd.’s quoted price sits in the lower half of its reported 52-week range, 31.54% below the high.
$1.00-$0.03 (-2.91%)
Pluristem Therapeutics Inc.: Healthcare · Biotechnology.
$2.93-$0.05 (-1.68%)
Cerecor Inc.’s quoted price sits in the lower half of its reported 52-week range, 1.68% below the high.
$7.56+$0.29 (+3.99%)
Eyenovia, Inc.’s quoted price sits in the lower half of its reported 52-week range, 93.94% below the high.
$4.34$0.00 (0.0%)
Lumos Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.15% below the high.
$0.65-$0.13 (-16.81%)
Rite Aid Corporation’s quoted price sits in the lower half of its reported 52-week range, 91.2% below the high.
$1.10$0.00 (0.0%)
Satsuma Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 86.39% below the high.
